Angiogenesis Research to Improve Therapies for Vascular Leak Syndromes, Intra-Abdominal Adhesions, and Arterial Injuries
Final addendum, 24 Mar 2008-23 Mar 2009
CHILDREN'S HOSPITAL CORP BOSTON MA
Pagination or Media Count:
The three goals of this project are i to discover and develop novel drugs which could prevent or reverse the vascular leak syndrome ii to develop angiogenesis inhibitors which would inhibit post-operative abdominal adhesions and, iii to isolate endothelial progenitor cells from blood, capable of being expanded in vitro and applied to vascular grafts. Progress has been made in each category we have made considerable progress in determining the efficacy of three anti-angiogenic agents in preventing vascular permeability in experimental model systems we have developed a new blood cleansing platform that may have great value for treatment of infected patients with sepsis we established that sunitinib prevents and reduces postoperative intra-abdominal adhesions in rabbits at a dose of 10 mgkdday we determined that sunitinib reduces bowel anastomotic bursting pressure when used at the current dose and duration of treatment we have shown that the human EPCMPC system for building vascular networks is versatile in that it occurs in a variety of 3-dimensional environments, and that a transient influx of murine neutrophils 1-2 days after implantation of EPCsMPCsMatrigel is an important contributor to vasculogenesis.
- Medicine and Medical Research